Navigation Links
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Date:3/20/2008

- By targeting interleukin-6 receptors, ACTEMRA provides significant

benefits for patients when compared with existing therapies -

NUTLEY, N.J., March 20 /PRNewswire/ -- Patients with rheumatoid arthritis treated with Roche's ACTEMRA(TM) (tocilizumab) experienced significant and rapid reduction in the signs and symptoms of their disease, according to a study published in this week's issue of The Lancet. Results from the OPTION (TOcilizumab Pivotal Trial in Methotrexate Inadequate respONders) trial -- a Phase III international study -- demonstrated that RA patients achieved greater improvement of symptoms and a higher quality-of-life with ACTEMRA, an interleukin-6 (IL-6) receptor inhibitor, in combination with methotrexate, compared with methotrexate plus placebo.

"Results of this pivotal study convincingly demonstrate that tocilizumab can effectively and rapidly diminish the painful and debilitating effects of rheumatoid arthritis," said Josef Smolen, M.D., lead investigator of the OPTION trial and Professor of Medicine at the Department of Internal Medicine at the Medical University of Vienna, Austria. "These trial findings are significant because we know that many rheumatoid arthritis patients continue to experience symptoms of joint pain, stiffness, physical disability and fatigue, despite treatment with existing therapies."

About OPTION Study

In the OPTION trial, a three-arm, double-blind, controlled Phase III study, 623 patients were randomized to receive ACTEMRA intravenously (either 4mg/kg or 8mg/kg) every four weeks plus methotrexate weekly or placebo infusions plus methotrexate weekly. The study was conducted in 73 trial sites in 17 countries outside the United States.

At 24 weeks, 58.5% of ACTEMRA patients (8mg/kg) achieved a 20% reduction in RA symptoms (ACR20)(1), compared with 26.5% of patients in placebo plus methotrexate patients. In the study, 43.9% of patients treated with ACTEMRA (8mg/kg) plus meth
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015 The Physician-Patient Alliance for ... July 28, 2015, "Surviving Your Hospital Stay: Physician-Patient ... Patient Safety." A sentence was omitted ... "PPAHS is a member of the National ... more information on the National Coalition to Promote ...
(Date:7/31/2015)... LONDON , July 31, 2015 ... to decades of experience, the domestic pharmaceutical industry is ... today manufacture products to high international standards. ... well known is in sub-Saharan Africa: Morocco has quietly ... after South Africa . Indeed, Moroccan ...
(Date:7/31/2015)... , July 31, 2015  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, asthma ... of Yujiro S. Hata to its board ... in business and corporate development is a tremendous asset ... president and chief executive officer of Xencor. "Xencor faces ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... 16 Berlin Heart Inc. today announced,its EXCOR(R) Pediatric ... ongoing IDE clinical trial in the United,States of America. ... the Investigational Plan for the IDE study of the ... approval for the prospective,IDE study to begin initially at ...
... Australia, Oct. 16 Cytopia Limited (ASX:,CYT) will ... two important,scientific meetings this month., Dr Emmanuelle ... a,lecture entitled Targeted JAK2 Inhibitors for Myeloproliferative Disorders,at ... Australia and New,Zealand, in Perth, Australia, on 21 ...
Cached Medicine Technology:Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 2Berlin Heart's EXCOR(R) Pediatric Receives Unconditional Investigational Device Exemption (IDE) Approval 3Cytopia Scientific Presentations on JAK2 Inhibitor Program 2
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of ... Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto ... in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, ...
(Date:7/31/2015)... ... ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and black ... Exilis non-surgical fat reduction in New York. Due to its unparalleled level of ... Many patients travel to New York to get their non-surgical skin tightening and ...
(Date:7/31/2015)... ... 2015 , ... The 2nd annual Ride to Fight On will start and ... 2015. The Ride to Fight On is a cycling fundraiser that benefits the West ... Clinic and The University of Tennessee Health Science Center. A health and wellness festival ...
(Date:7/31/2015)... ... 31, 2015 , ... Jacksonville-based drug and alcohol rehabilitation center, ... Center. The medical community, social workers, law enforcement, and government officials are all ... the effort to better understand and combat sex trafficking. Lead by sex trafficking ...
(Date:7/31/2015)... , ... July 31, 2015 , ... M3 USA MDLinx.com, ... to launch three new Board Exam Courses. , The additions of Gastroenterology, Pulmonology ... Exam Prep from MDLinx makes preparing for the exam easy and painless. MDLinx ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3
... cholesterol lowering drugs known as statins may help prevent future ... The study is published in the August 2, 2011, print ... American Academy of Neurology. "Because the cause of ... drugs are often not used to prevent further strokes or ...
... , MONDAY, Aug. 1 (HealthDay News) -- Teens are ... in or go to school in neighborhoods with many fast ... study finds. Researchers compared 2007 data on junk food ... of junk food outlets, such as fast food restaurants, convenience ...
... By Amanda Gardner HealthDay Reporter , MONDAY, Aug. ... who have been prescribed a controlled medication such as Oxycontin ... are misusing the drugs, a new study has found. ... abuse other substances and to start giving or selling drugs ...
... , Prostate cancer is the number two killer of American men, ... affects more than 2 million American men, and in 2010 there ... kills, but even for those who survive it, the world is ... and depression are common after-effects of prostate cancer, and until now ...
... By Serena Gordon HealthDay Reporter , MONDAY, Aug. ... of the omega 3 fatty acid DHA during pregnancy, their ... indicates. At 1 month and 3 months of age, ... in the womb experienced cold symptoms, compared to about 45 ...
... of Technology (MIT) have developed a new imaging system ... changes in the esophagus or colon. The new system, ... Biomedical Optics Express , is based on an ... a way to see below the surface with 3-D, ...
Cached Medicine News:Health News:Cholesterol-lowering drugs may help prevent recurrent strokes in younger people 2Health News:With Junk Food Stores Nearby, Teens May Eat More of It 2Health News:When Teens Abuse Prescriptions, Addiction Often Follows 2Health News:When Teens Abuse Prescriptions, Addiction Often Follows 3Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 2Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 3Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 2Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 3Health News:New high-speed 3-D imaging system holds potential for improved cancer screening 4
Ernest nucleus cracker extra delicate cross-action serrated paddle shaped jaws for cracking the nucleus through a 2.5 mm incision....
Epilation forceps straight ends size 3.5"....
Removal Forceps, very fine pointed tips, with textured jaws, ideal for grasping wet sutures....
Forceps, extra delicate, straight....
Medicine Products: